

- **Name:** Kenjiro Namikawa
  - **Current Position & Affiliation:** Chief,  
Department of Dermatologic Oncology,  
National Cancer Center Hospital, Tokyo
  - **Country:** Japan
- 

• **Educational Background:**

Doctor of Philosophy (Medicine), University of Tsukuba, Ibaraki, Japan, 2011  
Doctor of Medicine, University of Tsukuba, Ibaraki, Japan, 2001

• **Professional Experience:**

2025 - present,  
Chief, Department of Dermatologic Oncology, National Cancer Center Hospital,  
Tokyo, Japan  
2018 - 2025,  
Head of Physicians, Department of Dermatologic Oncology, National Cancer Center  
Hospital, Tokyo, Japan  
2013 - 2014,  
Postdoctoral fellow, Department of Pathology, Dermatopathology Division,  
MD Anderson Cancer Center, Houston, TX, USA  
2007 - 2018,  
Attending Physician, Department of Dermatologic Oncology, National Cancer Center  
Hospital, Tokyo, Japan  
2006 - 2006,  
Clinical fellow, Department of Dermatology, University of Tsukuba, Ibaraki, Japan  
2003 - 2006,  
Clinical fellow, Department of Dermatologic Oncology, National Cancer Center  
Hospital, Tokyo, Japan  
2002 - 2003,  
Clinical fellow, Department of Dermatology, Mito Saiseikai General Hospital,  
Ibaraki, Japan  
2001 – 2002,  
Residency, Department of Dermatology, University of Tsukuba, Ibaraki, Japan

• **Professional Organizations:**

Japan Clinical Oncology Group (JCOG), Chair of Dermatologic Oncology Group  
(2022-present)  
Japanese Skin Cancer Society (JSCS), Board Member (2025-present)  
Japanese Association of Sarcoma Treatment and Research (JSTAR), Board Member  
(2025-present)  
Japanese Society of Medical Oncology (JSMO), Council Member (2022–present)

Japan Society of Clinical Oncology (JSCO), Member (2005–present)  
 Japanese Dermatological Association (JDA), Member (2001–present)  
 Japanese Society for Dermatologic Surgery (JADS), Member (2003–present)  
 American Society of Clinical Oncology (ASCO), Member (2015–present)  
 European Society for Medical Oncology (ESMO), Member (2018–present)  
 European Association of Dermato-Oncology (EADO), Member (2024–present)

### • Main Scientific Publications:

1. **Namikawa K**, Nakano E, Ogata D, Yamazaki N. Long-term survival with systemic therapy in the last decade: can melanoma be cured? *J Dermatol*. 2024;51(3):343-352.
2. **Namikawa K**, Ito T, Yoshikawa S, Yoshino K, Kiniwa Y, et al. Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study). *Cancer Med*. 2023;12(17):17967-17980.
3. **Namikawa K**, Kiyohara Y, Takenouchi T, Uhara H, Uchi H, et al. Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naïve advanced melanoma. *J Dermatol*. 2020;47(11):1257-1266.
4. **Namikawa K**, Takahashi A, Mori T, Tsutsumida A, Suzuki S, et al. Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study. *Melanoma Res*. 2020;30(1):76-84.
5. **Namikawa K**, Aung PP, Milton DR, Tetzlaff 1MT, Torres Cabala CA, et al. Correlation of tumor burden in sentinel lymph nodes with tumor burden in non-sentinel lymph nodes and survival in cutaneous melanoma. *Clin Cancer Res*. 2019;25(24):7585-7593.
6. **Namikawa K**, Yamazaki N. Targeted Therapy and Immunotherapy for Melanoma in Japan. *Curr Treat Options Oncol*. 2019; 20(1):7.
7. **Namikawa K**, Kiyohara Y, Takenouchi T, Uhara H, Uchi H, et al. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study. *Eur J Cancer*. 2018; 105:114-126.
8. **Namikawa K**, Aung PP, Gershenwald JE, Milton DR, Prieto VG. Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. *Cancer Med*. 2018; 7(3):583-593.